WebDUR001-106 : Brief Title: ... A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections : Secondary IDs: Study Status. WebJan 30, 2024 · Dalbavancin is a lipoglycopeptide antibiotic approved as a single- and two-dose regimen for adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms.
Dalbavancin Population Pharmacokinetic Modeling and …
WebSep 21, 2024 · Dalbavancin side effects. Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. … WebApr 24, 2015 · DALVANCE ® (dalbavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by … motherboard operating system
Efficacy and Safety of Dalbavancin for the Treatment of …
WebMar 1, 2024 · Dalbavancin injection is used to treat acute bacterial skin and skin structure infections (ABSSSI). It belongs to the group of medicines known as antibiotics. … WebJul 23, 2024 · NORTH CHICAGO, Ill., July 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved … WebOL, SD study investigating PK, safety, and tolerability of dalbavancin in hospitalized patients receiving standard IV anti-infective treatment for bacterial infections. 12–17 y. 10. 13. Patients weighing >60 kg: 1000 mg <60 kg: 15 mg/kg. 1. DUR001-106 (NCT01946568) 24. PK study of dalbavancin after IV SD dalbavancin ... 22.5 mg/kg. 3. DUR001 ... motherboard ooc09f6044959